<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019640</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0751</org_study_id>
    <secondary_id>NCI-2018-01239</secondary_id>
    <secondary_id>2015-0751</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03019640</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of cord blood-derived expanded allogeneic
      natural killer cells (umbilical cord blood natural killer [NK] cells), rituximab, high-dose
      chemotherapy, and stem cell transplant in treating patients with B-cell non-Hodgkin's
      lymphoma that has come back (recurrent) or that does not respond to treatment (refractory).
      Immune system cells, such as cord blood-derived expanded allogeneic natural killer cells, are
      made by the body to attack foreign or cancerous cells. Immunotherapy with rituximab, may
      induce changes in body's immune system and may interfere with the ability of tumor cells to
      grow and spread. Drugs used in chemotherapy, such as carmustine, cytarabine, etoposide,
      lenalidomide, melphalan, and rituximab, work in different ways to stop the growth of cancer
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading. A stem cell transplant using stem cells from the patient or a donor may be able to
      replace blood-forming cells that were destroyed by chemotherapy used to kill cancer cells.
      The donated stem cells may also replace the patient's immune cells and help destroy any
      remaining cancer cells. Giving cord blood-derived expanded allogeneic natural killer cells,
      rituximab, high-dose chemotherapy, and stem cell transplant may work better in treating
      patients with recurrent or refractory B-cell non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To establish the safety of this treatment by determining its treatment-related mortality
      (TRM) within 30 days.

      SECONDARY OBJECTIVES:

      I. To estimate the relapse-free survival (RFS). II. To estimate the overall survival (OS).
      III. To quantify duration of infused allogeneic umbilical cord blood (UCB)-derived natural
      killer (NK) cells in the recipient.

      OUTLINE:

      PREPARATIVE REGIMEN: Patients receive carmustine intravenously (IV) over 2 hours on day -12,
      etoposide IV twice daily (BID) over 3 hours on days -11 to -8, cytarabine IV BID over 1 hour
      on days -11 to -8, melphalan IV over 30 minutes on day -7, and lenalidomide orally (PO) once
      daily (QD) on days -7 to -2 in the absence of disease progression or unacceptable toxicity.
      Patients who are CD20+ also receive rituximab IV over 3 hours on days -13 and -7.

      NK-CELL INFUSION: Patients receive cord blood-derived expanded allogeneic NK cells IV over 1
      hour on day -5 in the absence of disease progression or unacceptable toxicity.

      STEM CELL TRANSPLANT: Patients undergo stem cell transplant IV over 30-60 minutes on day 0 in
      the absence of disease progression or unacceptable toxicity.

      POST-TRANSPLANT: Patients receive filgrastim subcutaneously (SC) QD beginning on day +5.
      Treatment continues until white blood cell count recovers in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30, 100, and 180 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality within 30 days (TRM30)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>TRM30 will be estimated using a 95% credible interval assuming a beta(.50, .50) prior.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>From the time of transplant assessed up to progression or relapse, assessed up to 3 years</time_frame>
    <description>Unadjusted RFS will be estimated by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From the time of transplant, assessed up to 3 years</time_frame>
    <description>Unadjusted OS will be estimated by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natural killer (NK) cell persistence</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>A Bayesian hierarchical regression model will be fit to the longitudinal NK cell data to assess its patterns over time and association with patient covariates, including type of lymphoma, age, and disease severity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Recurrent Diffuse Large B-Cell Lymphoma</condition>
  <condition>Recurrent Follicular Lymphoma</condition>
  <condition>Recurrent Indolent Adult Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Follicular Lymphoma</condition>
  <condition>Refractory Indolent Adult Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo stem cell transplant</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>Autologous Hematopoietic Cell Transplantation</other_name>
    <other_name>autologous stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>N,N''-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord Blood-derived Expanded Allogeneic Natural Killer Cells</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>Allogeneic CB-derived Ex vivo-expanded NK Cells</other_name>
    <other_name>CB-derived Expanded Allogeneic NK Cells</other_name>
    <other_name>UCB-derived Expanded Allogeneic NK Cells</other_name>
    <other_name>Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, NK infusion, stem cell transplant)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with B-cell lymphoma who are candidates to autologous stem-cell
             transplantation:

               -  Primary refractory or relapsed diffuse large B-cell lymphoma in response to
                  salvage treatment

               -  Primary refractory or relapsed follicular lymphoma or other indolent B-cell
                  histology in response to salvage treatment

               -  Chemosensitive mantle-cell lymphoma in first or later line of treatment

          -  Estimated serum creatinine clearance &gt;= 60 ml/min and a normal serum creatinine for
             age

          -  Serum glutamic-oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate
             transaminase (SGPT) =&lt; 3 x upper limit of normal (ULN)

          -  Total bilirubin and alkaline phosphatase (ALP) =&lt; 2 x ULN or =&lt; 3 x ULN for Gilbert's
             disease

          -  Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and
             diffusion lung capacity (DLCO) (corrected for hemoglobin [Hgb]) &gt;= 50% of the
             predicted value

          -  Left ventricular ejection fraction &gt;= 40%. No uncontrolled arrhythmias or symptomatic
             cardiac disease

          -  Performance status &lt; 2 (Eastern Cooperative Oncology Group [ECOG])

          -  Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential

        Exclusion Criteria:

          -  Primary central nervous system (CNS) lymphoma

          -  Grade &gt;= 3 non-hematologic toxicity from prior therapy that has not resolved to =&lt;
             grade (G) 1

          -  Prior whole brain irradiation

          -  Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg
             +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] &gt;= 10,000
             copies/mL, or &gt;= 2,000 IU/mL)

          -  Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
             hepatitis C or positive hepatitis C serology

          -  Active infection requiring parenteral antibiotics

          -  Human immunodeficiency virus (HIV) infection

          -  Radiation therapy in the month prior to enroll

          -  Breastfeeding females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago L Nieto</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yago Nieto</last_name>
    <phone>713-792-8750</phone>
    <email>ynieto@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yago L. Nieto</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Yago L. Nieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

